SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Gastroenterology, Hepatology and Nutrition

[Return To Index page]
photo Miguel D. Regueiro, MD

IBD Clinical Medical Director

Associate Chief for Education

Senior Medical Lead of Specialty Medical Homes

Co-Director, Total Care-IBD

Email: mdr7@pitt.edu

Phone: 412-647-7827

Contact
Office: Div. of Gastro., Hepatology & Nutrition-200 Lothrop St
UPMC Presbyterian Hospital M2 C Wing
Pittsburgh, PA 15213
 
Phone: 412-647-7827
Fax: 412-864-1204
E-mail: mdr7@pitt.edu
Administrative Assistant:
Deborah Cadman
Address: Division of Gastroenterology, Hepatology & Nutrition-200 Lothrop St
UPMC Presbyterian Hospital M2 PUH C-Wing
Pittsburgh, PA 15213
Email: cadmandj@upmc.edu
Phone: 412-647-4194
Fax: 412-864-1204
Administrative Assistant:
Paula Conwell
Address: Division of Gastroenterology, Hepatology & Nutrition- 200 Lothrop St
UPMC Presbyterian Hospital M2 PUH C-Wing
Pittsburgh, PA 15123
Email: filippinopa@upmc.edu
Phone: 412-647-7827
Fax: 412-864-1204
Education and Training
Education
BA, University of Pennsylvania, 1988
MD, Drexel (Hahnemann) University, 1992
Training
Internship, Internal Medicine, Beth Israel Hospital, Harvard Medical School, 1993
Residency, Internal Medicine, Beth Israel Hospital, Harvard Medical School, 1994
Fellowship, Gastroenterology, Beth Israel Hospital, Harvard Medical School, 1997
Clinical Investigator Training Program, MIT/Harvard Medical School, 1997
Research Interest
Dr. Regueiro is a Professor of Medicine whose research efforts involve inflammatory bowel disease (IBD) and specifically investigate the natural course of postoperative Crohn’s disease, medications to prevent Crohn’s disease recurrence, novel IBD medications, and phenotypes that correlate with genotypes for IBD. He has also recently developed interests in patient centered care and outcomes with the creation of the specialty medical home. This novel approach to IBD population-based health has led to research with the Health Plan (insurance company) on quality of life, clinical outcomes, and reduction in unplanned care.
Clinical Interest
Management of patients with Crohn's disease and ulcerative colitis. As part of a tertiary referral center, complex IBD patients are often referred for second opinion and assistant in treatment plans. Providing multidisciplinary, patient-centered care is a primary interest.
Educational Interest
Educating health care professionals and patients about the pathogenesis, natural course, and management of inflammatory bowel disease. Two areas of specific educational interest are teaching providers about therapeutic options for postoperative Crohn's disease and new models of care, e.g. specialty medical homes. Additionally, training gastroenterology fellows and residents has been a passion for the past 20 years.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, Pesci M, El-Hachem S, Harrison J, Binion D. Crohn's disease activity index dose not correlate with endoscopic recrrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011; Jan;17(1): 118-26.
Regueiro M, Rodemann J, Kip KE, Saul M, Swoger J, Baidoo L, Schwartz M, Barrie A, Binion D. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011; Apr;17(4): 1008-14.
Lazarev M, Ullman T, Schraut W, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010; May;16(5): 830-5.
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disase recurrence after ileal resection. Gastroenterology. 2009; Feb;136(2): 441-50.
Regueiro, M.D., Kip, K.E., Baidoo, L, Swoger, J.M., Schraut, W.H. Postoperative Therapy with Infliximab Prevents Long-Term Crohn’s Disease Recurrence. Clinical Gastroenterology Hepatology. 2014; 12: 1494-502.
Kip ,KE, Swoger, JM, Grandinetti, LM, Barrie, AM3rd, Greer, JB, Regueiro, MD. Tumor necrosis factor a antagonist-associated psoriasis in inflammatrory diseases:an analysis of the FDA adverse event reporting system. Inflammatory Bowel Disease. 2013; 19(6): 1164-72.
Regueiro, MD, Greer,JB, Binion, DG, Schraut, WH, Goyal, A, Keljo,DJ, Cross,RK, Williams, ED, Herfarth, HH, Siegel, CA, Oikonomou, I, Brand, MH, Hartman, DJ, Tublin,ME, Davis, PL, Baidoo, L, Szigethy, E, Watson, AR. The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflammatory Bowel Disease. 2014; 20(10): 1687-95.
Dassopoulos, T, Cohen, RD, Scherl, EJ, Schwartz, RM, Kosinski, L, Regueiro, MD. Ulcerative Colitis Care Pathway. Gastroenterology. 2015; 149(1): 238-45.
Regueiro, M, Feagan, BG, Zou, B, Johanns, J, Blank, MA, Chevrier, M, Plevy, S, Popp, J, Cornillie, FJ, Lukas, M, Danese, S, Gionchetti, P, Hanauer, SB, Reinisch, W, Sandborn, WJ, Sorrentine, D, Rutgeerts, P. PREVENT Study Group.Infliximab Reduces Endoscopic, but not Clinical, Recurrenece of Crohn's Disease Following Ileocolonic Resection. Gastroenterology. 2016.
Sponsored Research/Activities
Title: A Treatment Algorithm for the Prevention of Post-Operative Crohns Disease
Role: Co-Investigator
Funding Agency: Abbvie. Inc.
Start Year: 2015
End Year: 2017
Title: Evaluating a Prediction Tool and Decision Aid for Patients with Crohn's Disease
Role: Co-Investigator
Funding Agency: Dartmouth College/Agency for Healthcare Research and Quality
Grant Number: R01 HS021747
Start Year: 2013
End Year: 2016
Title: TELEmedicine in Patients with Inflammatory Bowel Disease: TELE-IBD
Role: Co-Investigator
Funding Agency: University of Maryland/Agency for Healthcare Research and Quality
Grant Number: R01 HS018975
Start Year: 2013
End Year: 2015
Title: NIDDK IBD Genetics Consortium Genetic Research Center
Role: Co-Investigator
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: U01 DK062420
Start Year: 2012
End Year: 2017
Title: A Prospective Multicenter Trial Evaluating the Benefit of Initial Surgically Established Drainage Prior to Medical Therapy for the Treatment of Crohns Perianal Fistulas
Role: Co-Investigator
Funding Agency: Vanderbilt University
Start Year: 2011
End Year: 2014
Title: Characterization of Anal Human Papillomavirus Infection, Anal Cytology, and Anal Dysplasia in the University of Pittsburgh Inflammatory Bowel Disease Cohort Study Before and at Least 4 months after Commencing a Non-Corticosteroid Immunosuppressive Agent
Role: Co-Investigator
Funding Agency: Merck
Grant Number: DRUG
Start Year: 2011
End Year: 2014
Title: Randomized, Double-blind, Prospective TRIAL Investigating the Efficacy of Methotrexate in Inductin and Maintenance of Steroid Free Remission in Ulcerative Colitis (Methotrexate Response in Treatment of UC - MERIT-UC)
Role: Co-Investigator
Funding Agency: University of North Carolina/National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: U01 DK092239
Start Year: 2011
End Year: 2014
Notable Achievements
Associate Editor, Inflammatory Bowel Diseases Journal, 2014
Fellow, American Gastroenterological Association, 2006
Fellow, American College of Gastroenterology, 2007
Fellow, American College of Physicians, 2011
Top Doctor, Pittsburgh, 2012 - present